In conclusion, in addition to the major role of reducing glucose calories at the renal level, the activation of signaling pathways and the influence of key enzymes recommend SGLT2 inhibitors as beneficial in metabolic syndrome. The gene discussed is SLC5A2; the disease is metabolic syndrome.